In December 2019, SARS-CoV-2 was freely spreading around the world. Natural immunity helped to lock away the virus. However, by December 2020, an emerging viral VoC entered the scene. Characterized by features such as convergent mutations (K417N, E484K and N501Y) encoding alterations to the RBD of the viral spike protein or numerous mutations to the region encoding the NTD of the spike protein, these variants could evade some aspects of natural defenses, such as certain antibody responses. Vaccines and mAbs are under clinical development to fight back against these emerging variants and hopefully provide a more secure way to contain SARS-CoV-2.